Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Equity Income (2018 - 2020)

Arcus Biosciences (RCUS) has 3 years of Equity Income data on record, last reported at -$131000.0 in Q2 2020.

  • For Q2 2020, Equity Income rose 68.2% year-over-year to -$131000.0; the TTM value through Mar 2021 reached -$131000.0, up 89.53%, while the annual FY2020 figure was -$613000.0, 49.0% up from the prior year.
  • Equity Income reached -$131000.0 in Q2 2020 per RCUS's latest filing, up from -$482000.0 in the prior quarter.
  • Across five years, Equity Income topped out at -$131000.0 in Q2 2020 and bottomed at -$482000.0 in Q1 2020.
  • Average Equity Income over 3 years is -$299888.9, with a median of -$323000.0 recorded in 2018.
  • Peak YoY movement for Equity Income: plummeted 172.85% in 2019, then skyrocketed 68.2% in 2020.
  • A 3-year view of Equity Income shows it stood at -$323000.0 in 2018, then dropped by 10.53% to -$357000.0 in 2019, then soared by 63.31% to -$131000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Equity Income were -$131000.0 in Q2 2020, -$482000.0 in Q1 2020, and -$357000.0 in Q3 2019.